to Advance Non-Invasive Cancer Detection in Lynch Syndrome.
Paris, September 2025 – MSInsight, a French precision oncology start-up, is proud to announce its participation in PREDI-LYNCH*, a six-year Horizon Europe consortium led by Oslo University Hospital. This ambitious project seeks to develop validated, non-invasive liquid biopsy tests to improve early cancer detection in people with Lynch syndrome (LS), one of the most common hereditary cancer syndromes.
The project launched in May 2025, and MSInsight is now pleased to share its role as a partner during Hereditary Cancer Awareness Week, underscoring the importance of raising awareness and building solutions for families at genetic risk of cancer.
